Abstract: An incretin analogue, a preparation method therefor, and the use thereof. The incretin analogue has a GLP-1R/GIPR/GCGR agonist activity, is a triple agonist, and can be used for lowering blood glucose, reducing fat and reducing weight.

Abstract: The present disclosure relates to the field of biology, in particular, to an anti-CLD18A2 VHH. The present disclosure provides an anti-CLD18A2 VHH. A complementarity determining region (CDR) of the anti-CLD18A2 VHH includes CDR1-CDR3 having amino acid sequences as shown below: CDR1 having an amino acid sequence represented by one of SEQ ID NO. 4-11, CDR2 having an amino acid sequence represented by one of SEQ ID NO. 19-26, and CDR3 having an amino acid sequence represented by one of SEQ ID NO.33-39. The anti-CLD18A2 VHH of the present disclosure can specifically bind to the epitope on CLD18A2, and the corresponding fusion protein thereof has good specificity and affinity for CLD18A2, and has a noticeable tumor suppression effect.

Abstract: The present disclosure provides a class of specific anti-PD-L1 single-domain antibodies that block PD-L1/PD-1 interaction, and humanized antibodies, fusion proteins, and pharmaceutical compositions prepared based on the single-domain antibodies, and use thereof.

Abstract: The present disclosure relates to the field of biology, in particular, to an anti-CLD18A2 VHH. The present disclosure provides an anti-CLD18A2 VHH. A complementarity determining region (CDR) of the anti-CLD18A2 VHH includes CDR1-CDR3 having amino acid sequences as shown below: CDR1 having an amino acid sequence represented by one of SEQ ID NO. 4-11, CDR2 having an amino acid sequence represented by one of SEQ ID NO. 19-26, and CDR3 having an amino acid sequence represented by one of SEQ ID NO.33-39. The anti-CLD18A2 VHH of the present disclosure can specifically bind to the epitope on CLD18A2, and the corresponding fusion protein thereof has good specificity and affinity for CLD18A2, and has a noticeable tumor suppression effect.

Abstract: The invention provides fusion proteins for treating an intestinal disease, having a structure as follows: R-L-P, wherein R is a GLP-2 receptor agonist; L is a peptide linker; and P is a long-acting carrier protein. The fusion protein provided by the invention has significant bioactivities and in vitro stability.

Abstract: The invention provides fusion proteins for treating an intestinal disease, having a structure as follows: R-L-P, wherein R is a GLP-2 receptor agonist; L is a peptide linker; and P is a long-acting carrier protein. The fusion protein provided by the invention has significant bioactivities and in vitro stability.

Abstract: The present invention relates to a mutant G-CSF fusion protein. The mutant G-CSF fusion protein is a fusion protein having the activity of stimulating the proliferation of neutrophilic granulocytes, and having a basic structure of G-CSF/carrier protein or carrier protein/G-CSF; wherein the G-CSF moiety comprises multipoint substitutions thus resulting in changes in biological activity and binding affinity. Compared with existing products, the mutant G-CSF fusion protein in the present invention has longer half-life and higher biological activity. Administration of the pharmaceutical preparation containing this mutant G-CSF fusion protein could be used in the treating neutropenia.

Abstract: The present invention relates to a mutant G-CSF fusion protein. The mutant G-CSF fusion protein is a fusion protein having the activity of stimulating the proliferation of neutrophilic granulocytes, and having a basic structure of G-CSF/carrier protein or carrier protein/G-CSF; wherein the G-CSF moiety comprises multipoint substitutions thus resulting in changes in biological activity and binding affinity. Compared with existing products, the mutant G-CSF fusion protein in the present invention has longer half-life and higher biological activity. Administration of the pharmaceutical preparation containing this mutant G-CSF fusion protein could be used in the treating neutropenia.